Literature DB >> 9105844

In vitro activity of an orally administered streptogramin (RPR 106,972) compared to quinupristin/dalfopristin and erythromycin.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

The antibacterial activities of RPR 106,972 and quinupristin/dalfopristin (RP 59,500) were determined by the broth microdilution susceptibility test method. No major differences were seen among MICs for 863 isolates representing 22 species. However, there were minor twofold differences in MICs for some species. On a weight-to-weight basis, the activities of the oral and parenteral streptogramins were essentially the same. Because the route of administration and the pharmacokinetics differ, it is not necessarily appropriate to extrapolate such in vitro observations to predict identical clinical and bacteriological response rates for the two drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105844     DOI: 10.1007/bf01709476

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  5 in total

Review 1.  Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.

Authors:  D E Low
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

2.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

4.  In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.

Authors:  D H Bouanchaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

5.  Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  R Leclercq; L Nantas; C J Soussy; J Duval
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

  5 in total
  2 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.